Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review.
10.7534/j.issn.1009-2137.2018.02.054
- VernacularTitle:CAR-T免疫治疗在血液肿瘤治疗中的研究现状和挑战
- Author:
Xin CHENG
1
,
2
;
Ya-Jie WANG
3
;
Shuai FENG
1
,
2
;
Ya-Yun WU
3
;
Tong-Hua YANG
3
;
Xun LAI
4
Author Information
1. Medical College of Kunming University of Science and Technology, Kunming 650000, Yunnan Province, China
2. Department of Hemato- logy, The First People's Hospital Affiliated to Kunming University of Science and Technology,Kunming 650000, Yunnan Province, China.
3. Department of Hemato- logy, The First People's Hospital Affiliated to Kunming University of Science and Technology,Kunming 650000, Yunnan Province, China.
4. Department of Hemato- logy, The First People's Hospital Affiliated to Kunming University of Science and Technology,Kunming 650000, Yunnan Province, China.E-mail: 1729112214@qq.com.
- Publication Type:Journal Article
- MeSH:
Antigens, CD19;
Hematologic Neoplasms;
therapy;
Humans;
Immunotherapy;
Immunotherapy, Adoptive;
Receptors, Antigen, T-Cell;
T-Lymphocytes
- From:
Journal of Experimental Hematology
2018;26(2):626-630
- CountryChina
- Language:Chinese
-
Abstract:
The chimeric antigen receptor (CAR) T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatibility complex (MHC), thus making a breakthrough in clinical treatment. In this review, the history, structure and mechanism of action of CAR-T, as well as the current status and challenges of CAR-T immunotherapy in acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma are summarized.
